Andrew Zolopa

Infectious disease doctor

Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center, Emeritus

Infectious Disease Clinic

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-736-5200
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: Santa Clara Valley Medical Center (1988) CA

Internship: Santa Clara Valley Medical Center (1985) CA

Fellowship: Stanford University School of Medicine (1992) CA

Board Certification: Internal Medicine, American Board of Internal Medicine (1988)

Medical Education: UCLA School of Medicine (1984) CA

Administrative Appointments

Acting Chief of Infectious Diseases, Stanford University, School of Medicine (2008 - 2010)

Low Baseline CD4(+) Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation
Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., & Brown, T. T. (2013). Low Baseline CD4(+) Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation. CLINICAL INFECTIOUS DISEASES, 57(10), 1483-1488.

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
Zolopa, A., Sax, P. E., deJesus, E., Mills, A., Cohen, C., & Szwarcberg, J. (2013). A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 63(1), 96-100.

Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms
Wood, B. R., Komarow, L., Zolopa, A. R., Finkelman, M. A., Powderly, W. G., & Sax, P. E. (2013). Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS, 27(6), 967-972.

Patient monitoring and follow-up in lentiviral clinical trials
McGarrity, G. J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., & Rebello, T. (2013). Patient monitoring and follow-up in lentiviral clinical trials. JOURNAL OF GENE MEDICINE, 15(2), 78-82.

Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164
Grant, P. M., Komarow, L., Lederman, M. M., Pahwa, S., Zolopa, A. R., & Sereti, I. (2012). Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. JOURNAL OF INFECTIOUS DISEASES, 206(11), 1715-1723.

When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!
Grant, P. M., & Zolopa, A. R. (2012). When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!. CURRENT HIV/AIDS REPORTS, 9(3), 251-258.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Sax, P. E., deJesus, E., Mills, A., Zolopa, A., Cohen, C., & Cheng, A. K. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. LANCET, 379(9835), 2439-2448.

Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility
Melikian, G. L., Rhee, S.-Y., Taylor, J., Fessel, W. J., Kaufman, D., & Shafer, R. W. (2012). Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(5), 2305-2313.

Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults
Eastburn, A., Scherzer, R., Zolopa, A. R., Benson, C., Tracy, R., & Tien, P. C. (2011). Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults. PLOS ONE, 6(11).

Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia
Sax, P. E., Komarow, L., Finkelman, M. A., Grant, P. M., Andersen, J., & Zolopa, A. R. (2011). Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia. CLINICAL INFECTIOUS DISEASES, 53(2), 197-202.

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis
Bendavid, E., Grant, P., Talbot, A., Owens, D. K., & Zolopa, A. (2011). Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS, 25(2), 211-220.

Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort
Tien, P. C., Choi, A. I., Zolopa, A. R., Benson, C., Tracy, R., & Grunfeld, C. (2010). Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 316-322.

Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis
Grant, P. M., Aberg, J. A., & Zolopa, A. R. (2010). Concerns Regarding a Randomized Study of the Timing of Antiretroviral Therapy in Zimbabweans with AIDS and Acute Cryptococcal Meningitis. CLINICAL INFECTIOUS DISEASES, 51(8), 984-985.

HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Rhee, S.-Y., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., & Shafer, R. W. (2010). HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(10), 4253-4261.

Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164
Sax, P. E., Sloan, C. E., Schackman, B. R., Grant, P. M., Rong, J., & Freedberg, K. A. (2010). Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. HIV CLINICAL TRIALS, 11(5), 248-259.

Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
Grant, P. M., & Zolopa, A. R. (2010). Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11(8), 901-910.

Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection
Grant, P. M., Komarow, L., Andersen, J., Sereti, I., Pahwa, S., & Zolopa, A. (2010). Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection. PLOS ONE, 5(7).

Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
Talbot, A., Grant, P., Taylor, J., Baril, J.-G., Liu, T. F., & Zolopa, A. (2010). Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2473-2479.

International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase
Grant, P. M., Taylor, J., Nevins, A. B., Calvez, V., Marcelin, A.-G., & Zolopa, A. R. (2010). International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(4), 1520-1525.

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial
Zolopa, A. R., Berger, D. S., Lampiris, H., Zhong, L., Chuck, S. L., & Cheng, A. K. (2010). Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial. JOURNAL OF INFECTIOUS DISEASES, 201(6), 814-822.

Development of a didanosene genotypic resistance interpretation system based on large derivation and validation datasets
Assoumou, L., Cozzi-Lepri, A., Brun-Vezinet, F., DeGruttola, V., Kuritzkes, D. R., & Costagliola, D. (2010). Development of a didanosene genotypic resistance interpretation system based on large derivation and validation datasets. AIDS, 24(3), 365-371.

Association of HIV Infection, Demographic and Cardiovascular Risk Factors With All-Cause Mortality in the Recent HAART Era
Cockerham, L., Scherzer, R., Zolopa, A., Rimland, D., Lewis, C. E., & Tien, P. C. (2010). Association of HIV Infection, Demographic and Cardiovascular Risk Factors With All-Cause Mortality in the Recent HAART Era. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 53(1), 102-106.

The evolution of HIV treatment guidelines: Current state-of-the-art of ART
Zolopa, A. R. (2010). The evolution of HIV treatment guidelines: Current state-of-the-art of ART. ANTIVIRAL RESEARCH, 85(1), 241-244.

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Grant, P. M., Palmer, S., Bendavid, E., Talbot, A., Slamowitz, D. C., & Zolopa, A. R. (2009). Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. JOURNAL OF CLINICAL VIROLOGY, 46(4), 305-308.

Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations
Shahriar, R., Rhee, S.-Y., Liu, T. F., Fessel, W. J., Scarsella, A., & Shafer, R. W. (2009). Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(11), 4869-4878.

The use of resistance testing in the management of HIV-1-infected patients
Grant, P. M., & Zolopa, A. R. (2009). The use of resistance testing in the management of HIV-1-infected patients. CURRENT OPINION IN HIV AND AIDS, 4(6), 474-480.

Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial
Zolopa, A. R., Andersen, J., Komarow, L., Sanne, I., Sanchez, A., & Powderly, W. (2009). Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLOS ONE, 4(5).

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.
Grant, P., & Zolopa, A. (2009). Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Current HIV/AIDS reports, 6(2), 63-67.

Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
Grant, P., Taylor, J., Cain, P., Short, W., Gallant, J., & Zolopa, A. (2009). Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. CLINICAL INFECTIOUS DISEASES, 48(5), 680-682.

Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir
Haas, D. W., Koletar, S. L., Laughlin, L., Kendall, M. A., Suckow, C., & Acosta, E. P. (2009). Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 50(3), 290-293.

Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patients: the Below the Level of Quantification Study
DeJesus, E., Gottlieb, M. S., Gathe, J. C., Greenberg, M. L., Guittari, C. J., & Zolopa, A. R. (2008). Safety and Efficacy of Enfuvirtide in Combination with Darunavir-Ritonavir and an Optimized Background Regimen in Treatment-Experienced Human Immunodeficiency Virus-Infected Patients: the Below the Level of Quantification Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(12), 4315-4319.

Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial
Sattler, F. R., Rajicic, N., Mulligan, K., Yarasheski, K. E., Koletar, S. L., & Bistrian, B. (2008). Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. AMERICAN JOURNAL OF CLINICAL NUTRITION, 88(5), 1313-1321.

Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores
Grant, P., Wong, E. C., Rode, R., Shafer, R., De Luca, A., & Zolopa, A. (2008). Virologic Response to Lopinavir-Ritonavir-Based Antiretroviral Regimens in a Multicenter International Clinical Cohort: Comparison of Genotypic Interpretation Scores. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4050-4056.

Initiatives for developing and comparing genotype interpretation systems: External validation of existing systems for didanosine against virological response
Assoumou, L., Brun-Vezinet, F., Cozzi-Lepri, A., Kuritzkes, D., Phillips, A., & Costagliola, D. (2008). Initiatives for developing and comparing genotype interpretation systems: External validation of existing systems for didanosine against virological response. JOURNAL OF INFECTIOUS DISEASES, 198(4), 470-480.

Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Grant, P., & Zolopa, A. (2008). Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Journal of HIV therapy, 13(2), 36-39.

Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
Acosta, E. P., Kendall, M. A., Gerber, J. G., Alston-Smith, B., Koletar, S. L., & Haas, D. W. (2007). Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(9), 3104-3110.

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Gulick, R. M., Su, Z., Flexner, C., Hughes, M. D., Skolnik, P. R., & Kuritzkes, D. R. (2007). Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211. JOURNAL OF INFECTIOUS DISEASES, 196(2), 304-312.

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)
Kilby, J. M., Bucy, R. P., Mildvan, D., Fischl, M., Santana-Bagur, J., & Mitsuyasu, R. (2006). A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). JOURNAL OF INFECTIOUS DISEASES, 194(12), 1672-1676.

N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure
Mitsuya, Y., Winters, M. A., Fessel, W. J., Rhee, S.-Y., Hurley, L., & Shafer, R. W. (2006). N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS RESEARCH AND HUMAN RETROVIRUSES, 22(12), 1300-1305.

Incorporating drug-resistance measurements into the clinical management of HIV-1 infection
Zolopa, A. R. (2006). Incorporating drug-resistance measurements into the clinical management of HIV-1 infection. JOURNAL OF INFECTIOUS DISEASES, 194, S59-S64.

The study of fat redistribution and metabolic change in HIV infection (FRAM): Methods, design, and sample characteristics
Tien, P. C., Benson, C., Zolopa, A. R., Sidney, S., Osmond, D., & Grunfeld, C. (2006). The study of fat redistribution and metabolic change in HIV infection (FRAM): Methods, design, and sample characteristics. AMERICAN JOURNAL OF EPIDEMIOLOGY, 163(9), 860-869.

The effect of diagnosis with HIV infection on health-related quality of life
Honiden, S., Sundaram, V., Nease, R. F., Holodniy, M., Lazzeroni, L. C., & Owens, D. K. (2006). The effect of diagnosis with HIV infection on health-related quality of life. QUALITY OF LIFE RESEARCH, 15(1), 69-82.

Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet.
Liu, M., Holodniy, M., Zolopa, A. R., & Shafer, R. W. (2006). Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. MedGenMed : Medscape general medicine, 8(1), 24-?.

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
Glesby, M. J., Aberg, J. A., Kendall, M. A., Fichtenbaum, C. J., Hafner, R., & Gerber, J. G. (2005). Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. CLINICAL PHARMACOLOGY & THERAPEUTICS, 78(2), 143-153.

HIV-1 protease and reverse-transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance
Rhee, S. Y., Fessel, W. J., Zolopa, A. R., Hurley, L., Liu, T., & Shafer, R. W. (2005). HIV-1 protease and reverse-transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. JOURNAL OF INFECTIOUS DISEASES, 192(3), 456-465.

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
Campbell, T. B., Shulman, N. S., Johnson, S. C., Zolopa, A. R., Young, R. K., & Kuritzkes, D. R. (2005). Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. CLINICAL INFECTIOUS DISEASES, 41(2), 236-242.

Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: An international comparison (The GUESS Study)
Zolopa, A. R., Lazzeroni, L. C., Rinehart, A., Vezinet, F. B., Clavel, F., & Kuritzkes, D. R. (2005). Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: An international comparison (The GUESS Study). CLINICAL INFECTIOUS DISEASES, 41(1), 92-99.

Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine
Lecossier, D., Shulman, N. S., Morand-Joubert, L., Shafer, R. W., Joly, V., & Hance, A. J. (2005). Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 38(1), 37-42.

Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study
Holodniy, M., Charlebois, E. D., Bangsberg, D. R., Zolopa, A. R., Schulte, M., & Moss, A. R. (2004). Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study. INTERNATIONAL JOURNAL OF STD & AIDS, 15(8), 543-551.

Clinically validated genotype analysis: guiding principles and statistical concerns
Brun-Vezinet, F., Costagliolo, D., Khaled, M. A., Calvez, V., Clavel, F., & DeGruttola, V. (2004). Clinically validated genotype analysis: guiding principles and statistical concerns. ANTIVIRAL THERAPY, 9(4), 465-478.

High levels of adherence do not prevent accumulation of HIV drug resistance mutations
Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., & Moss, A. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17(13), 1925-1932.

Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation
Gonzales, M. J., Delwart, E., Rhee, S. Y., Tsui, R., Zolopa, A. R., & Shafer, R. W. (2003). Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. JOURNAL OF INFECTIOUS DISEASES, 188(3), 397-405.

Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors
Gonzales, M. J., Wu, T. D., Taylor, J., Belitskaya, F., Kantor, R., & Shafer, R. W. (2003). Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS, 17(6), 791-799.

Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments
Wu, T. D., Schiffer, C. A., Gonzales, M. J., Taylor, J., Kantor, R., & Shafer, R. W. (2003). Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. JOURNAL OF VIROLOGY, 77(8), 4836-4847.

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
Shulman, N., Zolopa, A., Havlir, D., Hsu, A., Renz, C., & Sun, E. (2002). Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(12), 3907-3916.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients
Shulman, N. S., Hughes, M. D., Winters, M. A., Shafer, R. W., Zolopa, A. R., & Katzenstein, D. A. (2002). Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 31(2), 121-127.

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy
Kantor, R., Fessel, W. J., Zolopa, A. R., Israelski, D., Shulman, N., & Shafer, R. W. (2002). Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(4), 1086-1092.

Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART)
Morris, M. K., Katzenstein, D. A., Israelski, D., Zolopa, A., Hendry, R. M., & Hanson, C. V. (2001). Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART). JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 28(5), 405-415.

HIV drug resistance testing: an update for the clinician.
RICE, H. L., & Zolopa, A. R. (2001). HIV drug resistance testing: an update for the clinician. AIDS clinical care, 13(10), 89-?.

Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
Shulman, N. S., Machekano, R. A., Shafer, R. W., Winters, M. A., Zolopa, A. R., & Katzenstein, D. A. (2001). Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 27(4), 377-380.

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., & Moss, A. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181-1183.

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
Shulman, N., Zolopa, A. R., Passaro, D., Shafer, R. W., Huang, W., & Whitcomb, J. (2001). Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS, 15(9), 1125-1132.

High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
Shafer, R. W., Hertogs, K., Zolopa, A. R., Warford, A., Bloor, S., & Larder, B. A. (2001). High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. JOURNAL OF CLINICAL MICROBIOLOGY, 39(4), 1522-1529.

Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8(+) T cells
Gray, C. M., Lawrence, J., Ranheim, E. A., Vierra, M., Zupancic, M., & Merigan, T. C. (2000). Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8(+) T cells. AIDS RESEARCH AND HUMAN RETROVIRUSES, 16(14), 1357-1369.

Adherence to isoniazid prophylaxis in the homeless - A randomized controlled trial
Tulsky, J. P., Pilote, L., Hahn, J. A., Zolopa, A., Burke, M., & Moss, A. R. (2000). Adherence to isoniazid prophylaxis in the homeless - A randomized controlled trial. ARCHIVES OF INTERNAL MEDICINE, 160(5), 697-702.

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., & Moss, A. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357-366.

The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan
DeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., & Mellors, J. (2000). The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. ANTIVIRAL THERAPY, 5(1), 41-48.

Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
Shulman, N. S., Zolopa, A. R., Passaro, D. J., Murlidharan, U., Israelski, D. M., & Katzenstein, D. A. (2000). Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 23(3), 221-226.

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., & Efron, B. (1999). HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. ANNALS OF INTERNAL MEDICINE, 131(11), 813-?.

Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS
Eckburg, P. B., Zolopa, A. R., & Montoya, J. G. (1999). Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS. CLINICAL INFECTIOUS DISEASES, 29(1), 212-213.

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
Lawrence, J., Schapiro, J., Winters, M., Montoya, J., Zolopa, A., & Merigan, T. C. (1999). Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. JOURNAL OF INFECTIOUS DISEASES, 179(6), 1356-1364.

Association between time homeless and perceived health status among the homeless in San Francisco
White, M. C., Tulsky, J. P., Dawson, C., Zolopa, A. R., & Moss, A. R. (1997). Association between time homeless and perceived health status among the homeless in San Francisco. JOURNAL OF COMMUNITY HEALTH, 22(4), 271-282.

PREVALENCE OF MEASLES ANTIBODIES IN ADULTS WITH HIV-INFECTION - POSSIBLE RISK-FACTORS OF MEASLES SERONEGATIVITY
Kemper, C. A., Zolopa, A. R., Hamilton, J. R., Fenstersheib, M., Bhatia, G., & Deresinski, S. C. (1992). PREVALENCE OF MEASLES ANTIBODIES IN ADULTS WITH HIV-INFECTION - POSSIBLE RISK-FACTORS OF MEASLES SERONEGATIVITY. AIDS, 6(11), 1321-1325.